There’s been a huge amount of discussion surrounding including three-tier aggregation as part of serialization solutions, even for markets where it is not a legislative requirement.

Our CEO, Eric Tjoa, believes that despite aggregation adding complexity to the implementation process, the potential benefits far outweigh the initial investment. In this article with in-Pharma Technologist, Eric outlines the potential impact and benefits of aggregating products on the pharmaceutical supply chain.

Read the full article here: https://www.in-pharmatechnologist.com/Article/2017/09/27/The-track-trace-big-question-Can-we-get-around-aggregation-Or-should-we-get-ready